Laurus Labs Q3 FY26 Revenue Jumps 26% to ₹1,778 Cr, Net Profit Up 174%
Laurus Labs reported Q3 FY26 revenues of ₹1,778 crore (up 26% YoY) and net profit of ₹252 crore (up 174% YoY). For 9M FY26, revenues were ₹5,001 crore (up 30% YoY) and net profit was ₹610 crore (up 388% YoY). EBITDA margins improved significantly to 27.3% in Q3 and 26.1% for 9M. The company confirmed its full-year outlook for strong revenue growth and margin improvement.
The substantial increase in financial metrics like revenue, profit, and EBITDA, along with margin expansion and positive management outlook, indicates a significant positive impact on the company's financial performance and investor sentiment.
The company reported significant year-on-year growth in revenues, EBITDA, and net profit for both the quarter and nine-month periods. Margin expansion and positive management commentary also contribute to the positive sentiment.
Laurus Labs Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a significant increase in revenues for the third quarter of fiscal year 2026 (3Q FY26), reaching ₹1,778 crore, a 26% rise compared to ₹1,415 crore in the same period last year. EBITDA for the quarter surged by 70% to ₹485 crore, with EBITDA margins improving to 27.3% from 20.1% year-on-year. Net profit saw a substantial increase of 174%, reaching ₹252 crore, up from ₹92 crore in 3Q FY25. Diluted Earnings Per Share (EPS) stood at ₹4.7, a 176% increase from ₹1.7 in the prior year quarter.
For the nine months ended December 31, 2025 (9M FY26), Laurus Labs reported total revenues of ₹5,001 crore, marking a 30% growth over ₹3,834 crore in 9M FY25. EBITDA for the nine-month period more than doubled, growing by 104% to ₹1,303 crore, with EBITDA margins expanding to 26.1% from 16.6% year-on-year. Net profit for 9M FY26 reached ₹610 crore, a remarkable 388% increase from ₹125 crore in the previous year. Diluted EPS for the nine-month period was ₹11.3, up 391% from ₹2.3 in 9M FY25.
The company's Generics division showed strong performance with Q3 FY26 revenues at ₹1,327 crore, a 37% increase year-on-year, driven by higher ARV volumes and strong offtake in select molecules. The CDMO division reported revenues of ₹451 crore in 3Q FY26, a 1% increase year-on-year, with small molecules contributing ₹408 crore. The BIO division reported revenues of ₹43 crore in 3Q FY26, a 10% decrease year-on-year.
Dr. Satyanarayana Chava, Founder & CEO, commented that the results confirm the full-year outlook of strong revenue growth and improving margin momentum, with continued investments in peptide technology platforms and ADC/Gene therapy. V.V. Ravi Kumar, CFO, highlighted strong operational and financial performance, driven by the Generic business and CDMO small molecule offerings, with net debt leverage decreasing to 1.2x EBITDA. The company also announced its participation in an earnings conference call on Friday, January 23, 2026, at 5:00 p.m. IST.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.